

# Geraldine Ferron-brady

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/336783/publications.pdf>

Version: 2024-02-01

6  
papers

210  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

432  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Adaptive Physiologically Based Pharmacokineticâ€“Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 125-137.	2.0	7
2	Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 709-722.	2.5	7
3	Exposureâ€“response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , .	2.5	2
4	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	2.9	126
5	DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PvD) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 4-4.	1.4	18
6	Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all- <i>trans</i> retinoic acid in acute myeloid leukemia across subtypes. <i>Haematologica</i> , 2019, 104, 1156-1167.	3.5	50